Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma

ABSTRACT Introduction Atezolizumab plus bevacizumab (Atez/Bev) has become the standard first‐line therapy for advanced hepatocellular carcinoma (HCC), but optimal second‐line strategies remain unclear. This multicenter retrospective study compared survival outcomes and tumor control among first‐line...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Masanori Inoue, Sadahisa Ogasawara, Kazuhisa Asahara, Rui Sato, Shunji Watanabe, Haruka Anzai, Kazuo Tsubura, Taro Watabe, Makoto Fujiya, Teppei Akatsuka, Ryo Izai, Keiichi Katayama, Midori Sawada, Takahiro Tsuchiya, Chihiro Miwa, Ryohei Yoshino, Takuya Yonemoto, Kentaro Fujimoto, Hidemi Unozawa, Sae Yumita, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masato Nakamura, Naoya Kanogawa, Shingo Nakamoto, Masayuki Yokoyama, Jun Kato, Michihisa Moriguchi, Takeshi Aramaki, Naoki Morimoto
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-02-01
Colecção:	Cancer Medicine
Assuntos:	atezolizumab bevacizumab duration of disease control duration of response hepatocellular carcinoma second line
Acesso em linha:	https://doi.org/10.1002/cam4.71655
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!